NVCR News and Press, NovoCure Limited From 07/28/22

Novocure Ltd (NVCR) Q2 2022 Earnings Conference Call July 28, 2022, 08:00 ET Company Participants Ingrid Goldberg - VP, IR William Doyle - Executive Chairman Ashley Cordova - CFO Asaf Danziger - President, CEO & Director Uri Weinberg - Chief Science O...

NovoCure ( NASDAQ: NVCR ) is trading ~ 10% down after it posted wider-than-expected loss as costs increased during the quarter. The company posted Q2 GAAP EPS of -$0.23, which missed estimates by $0.09. NVCR also said top-line data from the LUNAR pivotal st...

NovoCure press release ( NASDAQ: NVCR ): Q2 GAAP EPS of -$0.23 misses by $0.09 . Revenue of $140.9M (+5.5% Y/Y) beats by $5.77M . Shares -1.9% PM. As of June 30, 2022, there were 3,454 active patients on therapy. Active patients from North America, EMEA...

Quarterly net revenues of $140.9 million, a 6% increase year-over-year Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2022. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cance...

NovoCure ( NASDAQ: NVCR ) is scheduled to announce Q2 earnings results on Thursday, July 28th, before market open. The consensus EPS Estimate is -$0.14 (flat Y/Y) and the consensus Revenue Estimate is $135.13M (+1.2% Y/Y). Over the last 3 months, EPS estimates have see...

Awards aim to promote and support innovative research on Tumor Treating Fields to deepen understanding and accelerate the development of new treatment strategies Novocure today announced the recipients of the 4 th Annual AACR-Novocure Grants for Tumor Treating Fields Res...

ShockWave’s disruptive approach within the calcified cardiovascular disease space creates a first-mover advantage offering the opportunity of robust sales growth. ShockWave Medical’s business model looks to “Grow Markets and Take Market Share” targeting an ...

There's a reason why the Rocky movies were so successful: Nearly everybody loves a comeback. That isn't just true in entertainment; investors like comeback stories, too. We asked three Motley Fool contributors to pick beaten-down stocks that they think could soar in the second half ...

Baillie Gifford’s 13F portfolio value decreased from ~$182B to ~$143B this quarter. They increased Affirm Holdings, Coupang, and Ginkgo Bioworks while reducing Petroleo Brasileiro and First Republic Bank. The top three positions are Tesla Motors, Moderna, and Illumina, and ...

The first half of the year is over. And good riddance. The S&P 500 experienced its worst first half in more than 50 years. Most investors saw the values of their holdings plunge. But the stock market won't remain in the doldrums forever. Here are three growth stocks that co...